Senores Pharmaceuticals Limited — Updates, 23-07-2025: Press Release

Senores Pharma reported robust Q1 FY26 consolidated financial results. Total Income surged 72% year-over-year to Rs 138 Cr, EBITDA increased 60% to Rs 34 Cr, and PAT jumped 95% to Rs 21 Cr. This strong performance was driven by Regulated Markets revenue growing 69% to Rs 90 Cr, and Emerging Markets revenue rising 32% to Rs 29 Cr. The company launched two new ANDA products and received approval for four others. Its CDMO/CMO segment is scaling up, and the Branded Generics business saw significant uptick. Senores also reported a positive operating cash flow of Rs 11 Cr.